Can we already reverse human aging, and does Sinclair's NMN/resveratrol/metformin stack do it?
Claim attributed to David Sinclair, PhD , Harvard Medical School genetics professor with real peer-reviewed lab work; also founder/investor in firms selling the compounds and biological-age tests he promotes (Sirtris, Metro Biotech, Animal Bioscience, Tally Health).
Two claims in one. That aging involves reversible epigenetic information loss is serious science, demonstrated in mice. That his NMN/resveratrol/metformin stack reverses aging in people is not supported by any human outcome data, and resveratrol's rationale largely collapsed.
Restoring a clock in a mouse eye is not a pill that reverses your aging, and the man selling the pills is the one telling you it works.
What it’s supposed to target
- Epigenetic information loss
- Sirtuins + NAD+
- Partial reprogramming (Yamanaka factors)
- Sirtuin-activating compounds
Sinclair's central theory is the Information Theory of Aging: the genome (the hardware) stays largely intact, but the epigenome (the software telling each cell which genes to run) gradually loses information, and that scrambling is what aging is. The corollaries follow: boosting NAD+ and sirtuins (his long-running interest, from resveratrol to NMN) should help cells maintain themselves, and, more radically, partial reprogramming with Yamanaka factors might reset the epigenetic software to a younger state. His lab's mouse work restoring sight by reprogramming is the strongest evidence for that last idea.
The basic science is real and, in the reprogramming case, genuinely exciting. The gap is the leap to the consumer shelf. Resveratrol, the original sirtuin-activator story, failed to translate (the company built on it was wound down); NMN reliably raises NAD+ but has no human outcome data on aging; partial reprogramming is mouse-stage with real cancer-risk questions. Add the commercial stakes, he co-founds and invests in companies selling tests and supplements adjacent to his claims, and the pattern is a serious scientist whose public “we can reverse aging now” framing runs ahead of the human evidence.
Mechanism is theory, not proof. A plausible pathway explains why something might work, not whether it does. The verdict rests on the evidence below, not the elegance of the theory.
What would have to be true
Aging is biologically malleable and epigenetic loss is reversible: HOLDS, supported in animal models.
Animal reprogramming results transfer to a human supplement stack: DOES NOT HOLD, pills are not AAV gene therapy.
NMN, resveratrol, or metformin show human aging outcomes: DOES NOT HOLD, surrogates only, resveratrol failed, metformin untested.
What the evidence actually shows
The basic science is legitimate, in mice
Sinclair's Information Theory of Aging holds that aging stems from loss of epigenetic information rather than DNA mutation, and that youthful patterns can be restored. The strongest support is Lu et al. 2020 (Nature): delivering three Yamanaka factors (OSK: Oct4, Sox2, Klf4) by AAV to mouse retinal ganglion cells reset DNA-methylation age, drove axon regeneration after optic-nerve crush, and reversed vision loss in aged and glaucomatous mice. This is real, peer-reviewed work. It is also a gene therapy in mice, not a supplement in people, and the paper carries Sinclair's disclosed inventor and Life Biosciences equity interests.
The consumer stack runs ahead of human evidence
Resveratrol failed to translate: the SIRT1-'activation' assay was shown to be a fluorescent-probe artifact, GSK bought Sirtris (~$720M, 2008), halted the SRT501 program around 2010 after Phase 2a kidney-failure events and weak efficacy, and shut Sirtris down in 2013. NMN reliably raises blood NAD+ in humans but trials report only safety or surrogate metabolic markers, never a healthspan or lifespan outcome. Metformin's longevity case is epidemiological; the pivotal TAME trial (3,000 adults aged 65 to 79) has sat partly funded (~$45 to $70M needed, NIA set aside ~$5M) and has not reported.
Studies, graded, and who paid
Lu et al. 2020 (Nature) restored vision in mice via partial reprogramming; peer-reviewed but mouse-only.
Human trials show raised NAD+ and surrogate metabolic signals only; no aging, healthspan, or lifespan endpoint.
SIRT1 'activation' assay was a fluorophore artifact; GSK's SRT501 program failed and Sirtris was shut down.
Epidemiology plus surrogates only; the pivotal TAME trial remains partly funded and unreported.
| # | Study | Type | Size | Funding / COI | Key limitations |
|---|---|---|---|---|---|
| 1 | Lu et al. 2020, Nature: reprogramming restores vision in mice | Animal experimental (mouse), peer-reviewed | Multiple mouse cohorts (retinal ganglion cells) | Mixed Academic/NIH plus foundation; Sinclair is a named inventor and Life Biosciences/Iduna equity holder (disclosed). | Mouse-only; gene therapy, not a supplement; no lifespan endpoint. |
| 2 | Okabe et al. 2022, Frontiers in Nutrition: oral NMN safety and blood NAD+ | Randomized, double-blind, placebo-controlled trial | 30 healthy adults, 250 mg/day, 12 weeks | Industry-funded Funded by Mitsubishi Corporation Life Sciences; several authors were employees who prepared the NMN/placebo. | Endpoint was safety plus blood NAD+; no aging, healthspan, or lifespan outcome. |
| 3 | Sirtris/GSK resveratrol program history | Corporate and clinical history (encyclopedia, cited reporting) | n/a | Industry-funded Documents GSK's industry-funded SRT501 program and its 2010 termination. | Secondary summary; underlying assay-artifact and shutdown facts well documented. |
| 4 | GSK halts SRT501 (analyst report, 2010) | Industry/analyst report on a halted Phase 2a trial | Advanced multiple-myeloma patients; several developed renal failure | Industry-funded Reports on GSK-funded clinical program. | Single indication; documents failure, not aging efficacy. |
| 6 | TAME metformin trial status (2024) | News reporting on trial funding/status | Planned 3,000 adults aged 65 to 79, ~6-year trial | , Chronically underfunded; metformin is generic so no pharma sponsor. | Not yet reported; no human aging outcome exists. |
There is genuine consensus that aging is malleable and reversible in animal models, but no consensus that any over-the-counter NMN/resveratrol/metformin stack slows or reverses aging in humans.
Unproven ≠ disproven
For NMN and metformin the gap is untested, not disproven: no definitive human outcome trial has run. Resveratrol's sirtuin mechanism is the exception, it was tested and substantially failed.
Where claim and evidence diverge
Human anti-aging endpoints take years and tens of millions of dollars, and regulators do not recognize aging as an indication, so generic and supplement compounds rarely get definitive trials. That is why TAME has languished for roughly a decade.
The money trail
Sinclair's promoted interventions map onto his ventures: Sirtris (resveratrol; sold to GSK ~$720M, then shut down), Metro Biotech (NMN), Animal Bioscience (a pet 'age-reversal' supplement that triggered 2024 Academy resignations), and Tally Health (a methylation age test plus supplements). The one rigorously tested industry bet, GSK's resveratrol, failed; TAME stalls because no firm profits from generic metformin.
The honest read
Aging as a reversible process is real science, in animals. The claim that Sinclair's supplement stack reverses aging in humans is unsupported by outcome data: resveratrol failed, NMN shows only surrogates, and metformin's longevity trial has not reported.
What would change this verdict
A randomized human trial showing NMN, resveratrol, or metformin extends healthspan or lifespan, or delays multiple age-related diseases (e.g. a reported TAME).
A controlled human study showing a Sinclair-style stack reverses a validated, outcome-anchored measure of biological aging.
Sources
- Lu Y, Sinclair DA, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588:124-129.
- Okabe K, et al. Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood NAD+ in healthy subjects. Frontiers in Nutrition. 2022.
- Sirtris Pharmaceuticals (history of GSK acquisition, SRT501, and shutdown). Wikipedia, citing primary reporting.
- GlaxoSmithKline stops development of resveratrol drug SRT501. Biopharm Consortium, Dec 2010.
- As billionaires race to fund anti-aging projects, a much-discussed trial goes overlooked. STAT News, Aug 9, 2022.
- The TAME trial for metformin remains only partially funded. Fight Aging!, Apr 2024 (citing NPR).
- David A. Sinclair (company ties, conflicts, and peer pushback). Wikipedia, citing WSJ and journal reporting.
People also ask
- Can NMN slow or reverse aging in humans?
- No human outcome data support this. Trials show NMN raises NAD+ and shifts surrogate metabolic markers only, with no aging, healthspan or lifespan endpoint measured. The reversal claim is unsupported by hard outcomes.
- Does resveratrol extend lifespan or healthspan?
- The rationale largely collapsed. The SIRT1 activation finding was a fluorophore assay artifact, GSK's SRT501 program failed, and Sirtris was shut down. There is no human healthspan benefit established.
- Is aging reversal real science or hype?
- The framing that aging involves reversible epigenetic information loss is serious science, demonstrated in mice. A 2020 Nature study restored vision in mice via partial reprogramming. But that is mouse-only, not a pill that reverses human aging.
- Does metformin slow aging?
- The case rests on epidemiology and surrogate markers only. The pivotal TAME trial remains partly funded and unreported, partly because no firm profits from generic metformin, so a longevity benefit in humans is not established.
Part of our guide: Longevity influencers and protocols, fact-checked
Caveat is journalism, not medical advice. We check public claims against published evidence; we don’t diagnose, treat, or tell you what to take.